8-KThe WireRoutine
Reg FD Disclosure
Filed Jun 22, 2022 · 4y ago · Accession 0001493152-22-017445
Plain English
Material event — a significant development the company must disclose promptly.
Read the source below for the full document.
Filing text
View original ↗Securities and Exchange Commission, the information in this Item 7.01 disclosure, including Exhibit
99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be “filed” under the
Securities Exchange Act of 1934, as amended.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
Number
Description
99.1
2022 Annual Meeting of Stockholders presentation slides
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
June 22, 2022
PROVECTUS
BIOPHARMACEUTICALS, INC.
By:
/s/
Heather Raines
Heather
Raines
Chief
Financial Officer (Principal Financial Officer)
Filing details
- Ticker
- PVCT
- CIK
- 315545
- Form type
- 8-K
- Filing date
- Jun 22, 2022
- Report date
- Jun 22, 2022
- Document
- form8-k.htm
- Size
- 4.8 MB